Pierre Tennstedt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2029895/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer. American Journal of Pathology, 2012, 181, 401-412.	3.8	278
2	ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy. Clinical Cancer Research, 2011, 17, 5878-5888.	7.0	232
3	Neurovascular Structure-adjacent Frozen-section Examination (NeuroSAFE) Increases Nerve-sparing Frequency and Reduces Positive Surgical Margins in Open and Robot-assisted Laparoscopic Radical Prostatectomy: Experience After 11 069 Consecutive Patients. European Urology, 2012, 62, 333-340.	1.9	213
4	Phytochelatin Synthesis Is Essential for the Detoxification of Excess Zinc and Contributes Significantly to the Accumulation of Zinc Â. Plant Physiology, 2009, 149, 938-948.	4.8	201
5	Prognostic Utility of the Cell Cycle Progression Score Generated from Biopsy in Men Treated with Prostatectomy. Journal of Urology, 2014, 192, 409-414.	0.4	180
6	Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney International, 2018, 94, 1177-1188.	5.2	179
7	SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. Journal of Clinical Investigation, 2011, 121, 4257-4267.	8.2	153
8	Nerve-sparing Surgery Technique, Not the Preservation of the Neurovascular Bundles, Leads to Improved Long-term Continence Rates After Radical Prostatectomy. European Urology, 2016, 69, 584-589.	1.9	119
9	High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. European Journal of Cancer, 2013, 49, 1273-1279.	2.8	101
10	Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. Scientific Reports, 2016, 6, 39736.	3.3	96
11	RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma. International Journal of Cancer, 2013, 132, 2118-2126.	5.1	95
12	A Feasible and Time-efficient Adaptation of NeuroSAFE for da Vinci Robot-assisted Radical Prostatectomy. European Urology, 2014, 66, 138-144.	1.9	94
13	Intratumoral <scp>T</scp> but not <scp>B</scp> lymphocytes are related to clinical outcome in prostate cancer. Apmis, 2012, 120, 901-908.	2.0	77
14	A comparative study of robotâ€assisted and open radical prostatectomy in 10Â790 men treated by highly trained surgeons for both procedures. BJU International, 2019, 123, 1031-1040.	2.5	76
15	Brachyury expression predicts poor prognosis at early stages of colorectal cancer. European Journal of Cancer, 2011, 47, 1080-1085.	2.8	72
16	HPV status in patients with head and neck of carcinoma of unknown primary site: HPV, tobacco smoking, and outcome. Oral Oncology, 2012, 48, 1178-1184.	1.5	71
17	Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. Modern Pathology, 2014, 27, 1612-1620.	5.5	69
18	Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 459, 193-200.	2.8	67

#	Article	IF	CITATIONS
19	Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 235.e11-235.e16.	1.6	62
20	Vacuolar sequestration of glutathioneS-conjugates outcompetes a possible degradation of the glutathione moiety by phytochelatin synthase. FEBS Letters, 2006, 580, 6384-6390.	2.8	61
21	Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. European Urology, 2017, 71, 330-336.	1.9	57
22	Miliary Never-Smoking Adenocarcinoma of the Lung: Strong Association with Epidermal Growth Factor Receptor Exon 19 Deletion. Journal of Thoracic Oncology, 2011, 6, 199-202.	1.1	54
23	TMPRSS2-ERG Fusions Are Strongly Linked to Young Patient Age in Low-grade Prostate Cancer. European Urology, 2014, 66, 978-981.	1.9	54
24	External Validation of the CAPRA-S Score to Predict Biochemical Recurrence, Metastasis and Mortality after Radical Prostatectomy in a European Cohort. Journal of Urology, 2015, 193, 1970-1975.	0.4	50
25	Role of TP53 Mutations in Vulvar Carcinomas. International Journal of Gynecological Pathology, 2011, 30, 497-504.	1.4	49
26	Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma. Cancer, 2012, 118, 1268-1275.	4.1	48
27	Patterns of TPD52 overexpression in multiple human solid tumor types analyzed by quantitative PCR. International Journal of Oncology, 2014, 44, 609-615.	3.3	48
28	Use of Phosphodiesterase Type 5 Inhibitors May Adversely Impact Biochemical Recurrence after Radical Prostatectomy. Journal of Urology, 2015, 193, 479-483.	0.4	46
29	Short- and Long-term Functional Outcomes and Quality of Life after Radical Prostatectomy: Patient-reported Outcomes from a Tertiary High-volume Center. European Urology Focus, 2017, 3, 615-620.	3.1	44
30	Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer. European Journal of Cancer, 2013, 49, 2441-2448.	2.8	40
31	Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer. International Journal of Cancer, 2015, 137, 2354-2363.	5.1	39
32	Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with <scp>pN</scp> 1 prostate cancer treated with radical prostatectomy. BJU International, 2017, 119, 717-723.	2.5	39
33	Functional and oncological outcomes of patients aged <50 years treated with radical prostatectomy for localised prostate cancer in a <scp>E</scp> uropean population. BJU International, 2014, 114, 38-45.	2.5	37
34	Survival and overall treatment time after postoperative radio(chemo)therapy in patients with head and neck cancer. Head and Neck, 2016, 38, 1058-1065.	2.0	32
35	BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy. Cancer Letters, 2018, 423, 60-70.	7.2	31
36	Open and robotâ€assisted radical retropubic prostatectomy in men receiving ongoing lowâ€dose aspirin medication: revisiting an old paradigm?. BJU International, 2014, 114, 396-403.	2.5	29

#	Article	IF	CITATIONS
37	19q13 amplification is associated with high grade and stage in pancreatic cancer. Genes Chromosomes and Cancer, 2010, 49, 569-575.	2.8	25
38	Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies. BJU International, 2019, 123, 826-833.	2.5	25
39	Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer. BJUI Compass, 2020, 1, 15-20.	1.3	25
40	Prediction of Significant Prostate Cancer at Prostate Biopsy and Per Core Detection Rate of Targeted and Systematic Biopsies Using Real-Time Shear Wave Elastography. Urologia Internationalis, 2015, 95, 189-196.	1.3	23
41	The impact of the number of cores on tissue microarray studies investigating prostate cancer biomarkers. International Journal of Oncology, 2011, 40, 261-8.	3.3	22
42	Tumor volume in insignificant prostate cancer: Increasing threshold gains increasing risk. Prostate, 2015, 75, 45-49.	2.3	22
43	Loss of CDKN1B/p27Kip1 expression is associated with ERG fusion-negative prostate cancer, but is unrelated to patient prognosis. Oncology Letters, 2013, 6, 1245-1252.	1.8	21
44	Tumor-Associated Release of Prostatic Cells into the Blood after Transrectal Ultrasound-Guided Biopsy in Patients with Histologically Confirmed Prostate Cancer. Clinical Chemistry, 2020, 66, 161-168.	3.2	21
45	Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy. Strahlentherapie Und Onkologie, 2017, 193, 692-699.	2.0	19
46	Obesity paradox in prostate cancer: increased body mass index was associated with decreased risk of metastases after surgery in 13,667 patients. World Journal of Urology, 2018, 36, 1067-1072.	2.2	18
47	Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate Cancer. Scientific Reports, 2020, 10, 3250.	3.3	18
48	Role of cyclin D1 amplification and expression in vulvar carcinomas. Human Pathology, 2012, 43, 1386-1393.	2.0	16
49	Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer. PLoS ONE, 2017, 12, e0181557.	2.5	15
50	The zinc-finger transcription factor SALL4 is frequently expressed in human cancers: association with clinical outcome in squamous cell carcinoma but not in adenocarcinoma of the esophagus. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 483-492.	2.8	14
51	Prognostic factors for lymphedema in patients with locally advanced head and neck cancer after combined radio(chemo)therapy- results of a longitudinal study. Oral Oncology, 2020, 109, 104856.	1.5	14
52	Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma. World Journal of Urology, 2013, 31, 847-853.	2.2	13
53	High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer. Experimental and Therapeutic Medicine, 2013, 5, 102-106.	1.8	13
54	Additional androgen deprivation makes the difference. Strahlentherapie Und Onkologie, 2015, 191, 330-337.	2.0	13

#	Article	IF	CITATIONS
55	Predictors of short and long term urinary incontinence after radical prostatectomy in prostate MRI: Significance and reliability of standardized measurements. European Journal of Radiology, 2019, 120, 108668.	2.6	13
56	Risk assessment of metastatic recurrence in patients with prostate cancer by using the Cancer of the Prostate Risk Assessment score: results from 2937 European patients. BJU International, 2012, 110, 1714-1720.	2.5	12
57	Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. European Urology Focus, 2018, 4, 376-384.	3.1	12
58	Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 243-249.	1.6	11
59	The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. Prostate Cancer, 2018, 2018, 1-11.	0.6	10
60	Y chromosome losses are exceedingly rare in prostate cancer and unrelated to patient age. Prostate, 2012, 72, 898-903.	2.3	9
61	Accuracy of multiparametric MR imaging with PI-RADS V2 assessment in detecting infiltration of the neurovascular bundles prior to prostatectomy. European Journal of Radiology, 2018, 98, 187-192.	2.6	9
62	Characterization of Enterobacter cloacae Pneumonia: A Single-Center Retrospective Analysis. Lung, 2011, 189, 475-483.	3.3	8
63	Return to work following robot-assisted laparoscopic and open retropubic radical prostatectomy: A single-center cohort study to compare duration of sick leave. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 309.e1-309.e6.	1.6	8
64	Quality Aspects of TMA Analysis. Methods in Molecular Biology, 2010, 664, 17-26.	0.9	8
65	True targeting-derived prostate biopsy: HistoScanningâ,,¢ remained inadequate despite advanced technical efforts. World Journal of Urology, 2016, 34, 495-500.	2.2	7
66	Additional elastography-targeted biopsy improves the agreement between biopsy Gleason grade and Gleason grade at radical prostatectomy. World Journal of Urology, 2016, 34, 805-810.	2.2	7
67	The Impact of Repeat Prostate Biopsies on Oncologic, Pathological and Perioperative Outcomes after Radical Prostatectomy. Journal of Urology, 2017, 197, 103-108.	0.4	7
68	Poor Adherence to International Cancer Prevention Recommendations Among Patients With Prostate Cancer: First Results From the MARTINI-Lifestyle Cohort. European Urology Focus, 2020, 6, 935-940.	3.1	7
69	Comparison of Cognitive Function After Robot-Assisted Prostatectomy and Open Retropubic Radical Prostatectomy: A Prospective Observational Single-Center Study. Urology, 2020, 139, 110-117.	1.0	7
70	Patterns of ALK expression in different human cancer types. Journal of Clinical Pathology, 2014, 67, 477-481.	2.0	5
71	Carbonic anhydrase <scp>IX</scp> is strongly overexpressed in adenocarcinoma <i>inÂsitu</i> of the cervix uteri. Histopathology, 2014, 64, 600-602.	2.9	5
72	Histoscanning Has Low Sensitivity and Specificity for Seminal Vesicle Invasion. Urology, 2014, 84, 1168-1171.	1.0	5

#	Article	IF	CITATIONS
73	Oncological outcome after radical prostatectomy: Marital status does not make a difference. International Journal of Urology, 2015, 22, 484-489.	1.0	5
74	Differences in Patient Characteristics Among Men Choosing Open or Robot-Assisted Radical Prostatectomy in Contemporary Practice at a European High-Volume Center. Urologia Internationalis, 2016, 97, 8-15.	1.3	5
75	Prostate cancer rates in patients with initially negative elastography-targeted biopsy vs. systematic biopsy. World Journal of Urology, 2018, 36, 623-628.	2.2	5
76	Circulating Vitamin D and Selenium Levels and Outcome in Prostate Cancer Patients: Lessons from the MARTINI-Lifestyle Cohort. European Urology Focus, 2021, 7, 973-979.	3.1	5
77	Effect of repeat prostate biopsies on functional outcomes after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 91.e17-91.e22.	1.6	4
78	Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 575.e1-575.e7.	1.6	4
79	A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology. PLoS ONE, 2021, 16, e0259093.	2.5	4
80	CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo. Cancer Gene Therapy, 2022, 29, 49-61.	4.6	3
81	INVESTIGATION OF CA9 EXPRESSION IN PULMONAL METASTATIC LESIONS FROM PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA. Journal of Urology, 2008, 179, 136-136.	0.4	2
82	PD14-08 AMOUNT OF DISSECTED LYMPH NODES DURING RADICAL PROSTATECTOMY DOES NOT DEPEND ON SURGICAL APPROACH IN A SINGLE HIGH-VOLUME CENTER. Journal of Urology, 2014, 191, .	0.4	2
83	MP82-05 A COMPARISON OF DIFFERENT TREATMENT OPTIONS FOR LYMPH NODE-POSITIVE PROSTATE CANCER AT RADICAL PROSTATECTOMY. Journal of Urology, 2015, 193, .	0.4	2
84	Safe-R: a novel score, accounting for oncological safe nerve-sparing at radical prostatectomy for localized prostate cancer. World Journal of Urology, 2015, 33, 77-83.	2.2	2
85	Impact of surgeon-defined capsular incision during radical prostatectomy on biochemical recurrence rates. World Journal of Urology, 2016, 34, 1547-1553.	2.2	2
86	Significant reduction of lymphoceles after radical prostatectomy and pelvic lymph node dissection. BJU International, 2021, 128, 728-733.	2.5	2
87	Value of cell cycle progression (CCP) score to predict biochemical recurrence and definitive post-surgical pathology Journal of Clinical Oncology, 2013, 31, 5043-5043.	1.6	2
88	PD14-12 CLAVIEN IIIB COMPLICATIONS AFTER OPEN RETROPUBIC AND ROBOTIC-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY IN A SINGLE HIGH-VOLUME CENTER. Journal of Urology, 2014, 191, .	0.4	1
89	MP28-05 A COMBINATION OF NEW PROTEIN BIOMARKERS REDUCES UNNEEDED PROSTATE BIOPSIES AND IMPROVES THE DETECTION OF PROSTATE CANCER: FINDINGS OF A RECENT STUDY. Journal of Urology, 2017, 197, .	0.4	1
90	ABO/Rhesus Blood Group Does Not Influence Clinicopathological Tumor Characteristics or Oncological Outcome in Patients Undergoing Radical Prostatectomy. Frontiers in Surgery, 2017, 4, 75.	1.4	1

#	Article	IF	CITATIONS
91	Validation of the updated eighth edition of AJCC for prostate cancer: Removal of pT2 substages – Does extent of tumor involvement matter?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 637.e1-637.e7.	1.6	1
92	Effect of adjuvant and salvage radiotherapy after radical prostatectomy on urinary continence Journal of Clinical Oncology, 2014, 32, 100-100.	1.6	1
93	1426 TPD52 AS "8Q AMPLIFICATION TARGET" WITH STRONG PROGNOSTIC RELEVANCE IN PROSTATE CAN Journal of Urology, 2010, 183, .	NCER. 0.4	0
94	609 TMPRSS2-ERG GENE FUSION IS STRONGLY ASSOCIATED WITH ELEVATED ANDROGEN RECEPTOR EXPRESSION IN EARLY PROSTATE CANCER. Journal of Urology, 2011, 185, .	0.4	0
95	991 THE RATE OF ADVERSE DISEASE AND BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY IN PATIENTS ELIGIBLE FOR ACTIVE SURVEILLANCE. Journal of Urology, 2012, 187, .	0.4	0
96	375 FROZEN SECTION NAVIGATED RADICAL PROSTATECTOMY SIGNIFICANTLY INCREASE THE FREQUENCY OF NERVE-SPARING WITHOUT COMPROMISING ONCOLOGICAL OUTCOME. Journal of Urology, 2012, 187, .	0.4	0
97	380 FUNCTIONAL AND ONCOLOGICAL OUTCOME OF PATIENTS YOUNGER THAN 50 YEARS TREATED WITH RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER IN A NON SCREENED EUROPEAN POPULATION. Journal of Urology, 2012, 187, .	0.4	0
98	1361 RADICAL RETROPUBIC PROSTATECTOMY IS POSSIBLE WITH GOOD FUNCTIONAL RESULTS IN PATIENTS WITH PARKINSONS DISEASE OR STATUS POST STROKE. RESULTS FROM MORE THAN 13000 PATIENTS. Journal of Urology, 2012, 187, .	0.4	0
99	689 PATIENTS WITH LOW RISK FEATURES, OMITTED PELVIC LYMPH NODE DISSECTION (PLND) BUT PATHOLOGICALLY LOCALLY ADVANCED PROSTATE CANCERS (PT3A/PT3BNX) HAVE A BETTER ONCOLOGICAL OUTCOME THAN THEIR PT3A/PT3B PN0-COUNTERPARTS. Journal of Urology, 2012, 187, .	0.4	0
100	1342 RELATIONSHIP BETWEEN BLOOD LOSS, BLOOD TRANSFUSION AND BIOCHEMICAL RECURRENCE- RATES: ASSESSMENT OF 17347 RADICAL PROSTATECTOMY PATIENTS. Journal of Urology, 2012, 187, .	0.4	0
101	1640 USE OF PROERECTILE MEDICATION IS A SIGNIFICANT INDEPENDENT RISK FACTOR FOR PSA RECURRENCE IN PATIENTS AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2012, 187, .	0.4	0
102	360 SAFE-R: A NOVEL SCORE, ACCOUNTING FOR ONCOLOGICAL SAFE NERVE-SPARING. Journal of Urology, 2013, 189, .	0.4	0
103	V2160 INTRAOPERATIVE NEUROVASCULAR STRUCTURE-ADJACENT FROZEN-SECTION EXAMINATION (NEUROSAFE) INCREASES NERVE-SPARING FREQUENCY AND REDUCES POSITIVE SURGICAL MARGINS IN DAVINCI-ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY (DVP): EXPERIENCE AFTER 1157 CONSECUTIVE PATIENTS, Journal of Uralamy, 2013, 189	0.4	0
104	985 VALUE OF CELL CYCLE PROGRESSION (CCP) SCORE TO PREDICT BIOCHEMICAL RECURRENCE AND DEFINITIVE POST-SURGICAL PATHOLOGY. Journal of Urology, 2013, 189, .	0.4	0
105	356 RISK-FACTORS FOR BIOCHEMICAL RECURRENCE- AND CLINICAL METASTASIS-FREE SURVIVAL IN D'AMICO HIGH-RISK PATIENTS AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2013, 189, .	0.4	0
106	MP52-17 RECURRENT CHROMOSOMAL DELETIONS STATUS OBTAINED ON TISSUE CORES IS HIGHLY CORRELATED WITH LOCAL INVASIVE AND SYSTEMIC PROSTATE CANCER GROWTH. Journal of Urology, 2014, 191, .	0.4	0
107	MP58-06 BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY: IS EVERY PATIENT WITH A PSA OF 0.1NG/ML REALLY RECURRING?. Journal of Urology, 2014, 191, .	0.4	0
108	MP67-09 RISK ASSESSMENT TO PREDICT A POSITIVE BIOPSY USING SHEARWAVE ELASTOGRAPHY Journal of Urology, 2014, 191, .	0.4	0

#	Article	IF	CITATIONS
109	MP67-13 DOES HISTOSCANNING (â,,¢) PREDICT POSITIVE RESULTS IN PROSTATE BIOPSY? A RETROSPECTIVE ANALYSIS OF 1,188 SEXTANTS OF THE PROSTATE. Journal of Urology, 2014, 191, .	0.4	0
110	PD19-10 A POSITIVE SURGICAL MARGIN SIGNIFICANTLY INCREASES OVERALL MORTALITY AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2014, 191, .	0.4	0
111	MP79-15 PROGNOSTIC UTILITY OF THE CELL CYCLE PROGRESSION (CCP) SCORE GENERATED FROM NEEDLE BIOPSY IN MEN TREATED WITH PROSTATECTOMY. Journal of Urology, 2014, 191, .	0.4	0
112	MP51-18 ADJUVANT AND SALVAGE RADIOTHERAPY AFTER RADICAL PROSTATECTOMY DOES NOT COMPROMISE URINARY CONTINENCE. Journal of Urology, 2014, 191, .	0.4	0
113	PD15-05 PREDICTION OF LOCALLY ADVANCED PROSTATE CANCER AND TUMOR VOLUME WITH SHEARWAVE ELASTOGRAPHY PRIOR TO RADICAL PROSTATECTOMY: IMPACT ON ACTIVE SURVEILLANCE AND SELECTION FOR PROSTATE BIOPSY. Journal of Urology, 2014, 191, .	0.4	0
114	MP53-15 SHEARWAVE ELASTOGRAPHY FOR LOCALIZATION OF PROSTATE CANCER LESIONS AND ASSESSMENT OF ELASTICITY THRESHOLDS: IMPLICATIONS FOR TARGETED BIOPSIES AND ACTIVE SURVEILLANCE PROTOCOLS. Journal of Urology, 2014, 191, .	0.4	0
115	MP83-06 IS INVERSE STAGE MIGRATION A SUSTAINING PHENOMENON IN PATIENTS UNDERGOING RADICAL PROSTATECTOMY?. Journal of Urology, 2015, 193, .	0.4	0
116	MP55-08 GENOMIC DELETION OF CHROMOSOME 12P IS AN INDEPENDENT PROGNOSTIC MARKER IN PROSTATE CANCER. Journal of Urology, 2015, 193, .	0.4	0
117	MP83-05 THE EFFECT OF NERVE-SPARING ON URINARY CONTINENCE AFTER RADICAL PROSTATECTOMY: IS IT THE PRESERVATION OF THE NEUROVASCULAR BUNDLES OR THE SURGICAL TECHNIQUE WHICH LEADS TO IMPROVED CONTINENCE RATES?. Journal of Urology, 2015, 193, .	0.4	0
118	MP78-18 IMPACT OF CAPSULAR INCISION DURING RADICAL PROSTATECTOMY ON BIOCHEMICAL RECURRENCE RATES. Journal of Urology, 2015, 193, .	0.4	0
119	MP57-06 RADICAL PROSTATECTOMY AFTER REPEAT BIOPSY: ONCOLOGICAL AND PERIOPERATIVE OUTCOME. Journal of Urology, 2016, 195, .	0.4	0
120	PD03-12 APPLYING SEVEN CONTEMPORARY ACTIVE SURVEILLANCE PROTOCOLS TO PATIENTS UNDERGOING RADICAL PROSTATECTOMY: SIGNIFICANT DIFFERENCES IN MIDTERM ONCOLOGICAL OUTCOMES. Journal of Urology, 2016, 195, .	0.4	0
121	MP28-03 ALTERATION OF METASTATIC BEHAVIOR BY SHRNA MEDIATED KNOCKDOWN (KD) OF CHD1 IN HUMAN PROSTATE XENOGRAFT TUMORS AND CLINICAL OUTCOME OF PATIENTS WITH CHD1 DELETION. Journal of Urology, 2017, 197, .	0.4	0
122	MP47-04 OBESITY WAS ASSOCIATED WITH IMPROVED METASTASES-FREE SURVIVAL AFTER SURGERY IN 13,667 PROSTATE CANCER PATIENTS. Journal of Urology, 2017, 197, .	0.4	0
123	MP03-12 ACCURACY OF MULTIPARAMETRIC MR IMAGING WITH PI-RADS V2 ASSESSMENT IN DETECTING INFILTRATIONS OF THE NEUROVASCULAR BUNDLES PRIOR TO PROSTATECTOMY. Journal of Urology, 2017, 197, .	0.4	0
124	MP47-03 IMPACT OF ADDITIONAL RADIATION AND/OR ADT ON FUNCTIONAL OUTCOMES AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2017, 197, .	0.4	0
125	MP97-14 FUNCTIONAL OUTCOME OF RADICAL PROSTATECTOMY AFTER REPEAT BIOPSY. Journal of Urology, 2017, 197, .	0.4	0
126	Abstract 334: Comparison of an in situ hybridization technique based on fluorescence (FISH) with dual color silver-enhanced ISH (SISH) for the validation of equivocal (borderline) status of HER2 (erbb2) in invasive breast carcinoma. , 2010, , .		0

#	Article	IF	CITATIONS
127	Abstract 3291: Defining the role of the cellular polarity regulator Scrib in epithelial tumorigenesis. , 2012, , .		0
128	Prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with prostatectomy Journal of Clinical Oncology, 2014, 32, 17-17.	1.6	0
129	Correlation between recurrent chromosomal deletions status obtained on tissue cores and local invasive and systemic prostate cancer growth Journal of Clinical Oncology, 2014, 32, 24-24.	1.6	0
130	A feasible and time-efficient adaption of the neurosafe intraoperative frozen section technique to robotic-assisted radical prostatectomy Journal of Clinical Oncology, 2014, 32, 147-147.	1.6	0
131	Redefining postprostatectomy biochemical progression: The significance of a PSA cutoff below 0.2 ng/ml—Results from two retrospective series with and without salvage radiotherapy Journal of Clinical Oncology, 2015, 33, 153-153.	1.6	0
132	Toxicity in a multimodality approach of radical prostatectomy with radiation and hormonal therapy Journal of Clinical Oncology, 2016, 34, 107-107.	1.6	0
133	Validation of cAMP phosphodiesterase-4D7 (PDE4D7) for its independent contribution to risk stratification in a prostate cancer patient cohort with longitudinal biological outcomes Journal of Clinical Oncology, 2017, 35, 5069-5069.	1.6	0
134	Cohort study of oligorecurrent prostate cancer patients: Oncological outcomes of patients treated with salvage lymph node dissection via PSMA radioguided surgery Journal of Clinical Oncology, 2022, 40, 106-106.	1.6	0
135	Cohort study of patients with oligorecurrent prostate cancer: Oncological outcomes of patients treated with salvage lymph node dissection via PSMA radioguided surgery Journal of Clinical Oncology, 2022, 40, 5009-5009.	1.6	Ο